JAZZ 167.18 Jazz Pharmaceuticals $JAZZ Hit a 52 we
Post# of 76
JAZZ Recent Posts: http://investorshangout.com/Jazz-Pharmaceuticals-JAZZ-54526/
JAZZ Jazz Pharmaceuticals Recent Headline News
Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:20PM CST
Jazz Pharmaceuticals' (JAZZ) third-quarter 2014 adjusted earnings of $2.07 per share were above the year-ago adjusted earnings.
BIIB: 319.55 (-2.51), JAZZ: 167.18 (-1.30), AMAG: 33.78 (-0.32)
Stocks Open To Staggered Gains; Time Warner, NXP, Jazz Climb
at Investor's Business Daily - Wed Nov 05, 9:38AM CST
Stocks jumped off to modest gains in mixed trade early Wednesday. The S&P 500 led with a 0.4% advance. The Dow Jones industrial average climbed 0.3% and the Nasdaq added 0.1%. Volume rose 20% on the Nasdaq and dipped 4% on the NYSE. The stock market...
JAZZ: 167.18 (-1.30), TRIP: 71.95 (-11.84), NXPI: 73.36 (+3.69), TMH: 57.16 (-4.86), TWX: 77.99 (+3.02)
Jazz Pharmaceuticals Public (JAZZ) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 7:50AM CST
The following Jazz Pharmaceuticals Public (JAZZ) conference call took place on November 4, 2014, 04:30 PM ET. This is a transcript of that earnings call:
JAZZ: 167.18 (-1.30)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 196.32 (+1.20), BIIB: 319.55 (-2.51), VRX: 131.91 (-1.70), ACT: 247.91 (+2.59), JAZZ: 167.18 (-1.30), ALXN: 189.89 (-1.41), CELG: 105.15 (-0.60)
Top Funds Buy Ulta Beauty, Alexion, Avago
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Managers of leading mutual funds in recent months have continued to stock up on large medical stocks, such as Illumina (ILMN), Alexion Pharmaceuticals (ALXN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ),Allergan (AGN) and Centene (CNC). The...
AMBA: 44.71 (-0.77), MNST: 99.17 (-0.87), SWKS: 60.88 (+0.46), GMCR: 150.46 (-1.65), ILMN: 186.37 (-5.04), WSM: 64.73 (+0.40), NXPI: 73.36 (+3.69), CELG: 105.15 (-0.60), HAIN: 105.66 (-1.13), AGN: 196.32 (+1.20), CNC: 92.49 (+0.45), V: 249.53 (+6.56), CALM: 41.91 (-1.24), JAZZ: 167.18 (-1.30), ALXN: 189.89 (-1.41), LOW: 56.94 (-0.32), ULTA: 118.66 (-1.45), MA: 85.99 (+2.00), AVGO: 86.71 (+1.35), PETM: 70.40 (-0.30)
Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 230.97 (-7.96), ACT: 247.91 (+2.59), FEYE: 29.12 (-5.13), AWAY: 28.58 (-5.17), CYBR: 33.80 (-2.73), JAZZ: 167.18 (-1.30), TRIP: 71.95 (-11.84), PANW: 102.52 (-4.19), ATHM: 44.08 (-6.11)
Jazz Pharmaceuticals Announces Third Quarter 2014 Financial Results And Updated Guidance
PR Newswire - Tue Nov 04, 3:05PM CST
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2014 and updated financial guidance for full year 2014.
JAZZ: 167.18 (-1.30)
Stocks Turn Mixed; Epam Bounces Back
at Investor's Business Daily - Tue Nov 04, 2:13PM CST
Stocks continued to improve late Tuesday, turning mixed. The Dow Jones industrial average bounced back from a 0.5% loss and was up a fraction. The broader Nasdaq and the S&P 500 were off 0.4% each. They had been off 0.9% and 0.8%, respectively. NYSE...
FEYE: 29.12 (-5.13), AWAY: 28.58 (-5.17), FRGI: 58.00 (+2.58), SAVE: 75.41 (-1.21), LNKD: 218.18 (-20.25), SCTY: 54.44 (-2.52), STE: 62.66 (+0.22), PZZA: 49.52 (+2.82), JAZZ: 167.18 (-1.30), FL: 52.71 (-0.92), EPAM: 48.25 (+1.64)
Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 24.00 (+0.02), AGN: 196.32 (+1.20), ACT: 247.91 (+2.59), SWKS: 60.88 (+0.46), AKRX: 41.68 (-0.96), JAZZ: 167.18 (-1.30), SLXP: 139.50 (-0.95), AAPL: 108.86 (+0.26), ATHM: 44.08 (-6.11)
Sprint, RetailMeNot Disappoint The Street After Hours
at Investor's Business Daily - Mon Nov 03, 3:57PM CST
Stocks finished mixed Monday, with volume lower across the board. Oil dropped more than $2 a barrel and was trading near $78. After the close, wireless carrier Sprint (S) dropped sharply after announcing disappointing Q4 results. It reported a loss...
LCI: 53.15 (-3.10), S: 4.92 (-0.26), JAZZ: 167.18 (-1.30), SALE: 14.54 (+0.19), KORS: 72.40 (+0.98), PCLN: 1,095.34 (-2.36), BABA: 108.67 (+2.60)
Video: 4 Top-Rated Stocks Reporting Earnings Tuesday
at Investor's Business Daily - Mon Nov 03, 1:32PM CST
Alibaba, the world's largest IPO to date, is set to report its first quarterly earnings as a public company before the open on Tuesday. Analysts expect the Chinese e-commerce giant to earn 45 cents a share, excluding items, on revenue of $2.6...
JAZZ: 167.18 (-1.30), REGN: 368.51 (-3.88), BKW: 32.98 (+0.79), BABA: 108.67 (+2.60)
IBD 50 Caps Impressive 2-Week Rally
at Investor's Business Daily - Fri Oct 31, 5:47PM CDT
The IBD 50 just capped its best two-week performance in more than three years -- a run that's produced a batch of breakouts. The index rallied 9.4% over the past two weeks. That's the best two-week period since July 2011, when the IBD 50 roared...
ODFL: 74.21 (-0.44), AAP: 149.37 (+0.93), AKRX: 41.68 (-0.96), ILMN: 186.37 (-5.04), NXPI: 73.36 (+3.69), CDW: 31.33 (+0.29), CELG: 105.15 (-0.60), BIDU: 237.70 (-4.26), GILD: 106.05 (-3.67), JAZZ: 167.18 (-1.30), FLT: 148.51 (-0.02), FL: 52.71 (-0.92), AAPL: 108.86 (+0.26), AVGO: 86.71 (+1.35)
Stocks End Week On Fine Note; LinkedIn Surges On Earnings
at Investor's Business Daily - Fri Oct 31, 3:29PM CDT
The market enjoyed another shot of institutional buying Friday, cheered by additional -- and unexpected -- stimulus measures by the Bank of Japan. Another round of healthy earnings reports and a rise in U.S. consumer confidence also fueled positive...
AMBA: 44.71 (-0.77), TSLA: 230.97 (-7.96), GPRO: 75.89 (-6.38), ACT: 247.91 (+2.59), FRGI: 58.00 (+2.58), LNKD: 218.18 (-20.25), JAZZ: 167.18 (-1.30), FLT: 148.51 (-0.02), EPAM: 48.25 (+1.64), REGN: 368.51 (-3.88), BABA: 108.67 (+2.60)
Stocks Hold Near Session Highs; Drugmakers Shine Again
at Investor's Business Daily - Fri Oct 24, 1:50PM CDT
Stocks looked poised to end the week on a positive note Friday. The Dow Jones industrial average added 0.6%; the S&P 500 rose 0.5% and the Nasdaq picked up 0.4%. NYSE was tracking lower than Thursday's level. Nasdaq volume was tracking close to...
AMZN: 296.52 (-6.29), SYNA: 65.85 (-0.82), EW: 121.10 (+1.32), SLXP: 139.50 (-0.95), MTX: 75.46 (-0.28), CELG: 105.15 (-0.60), GILD: 106.05 (-3.67), JAZZ: 167.18 (-1.30), ALXN: 189.89 (-1.41), PG: 89.00 (+0.36), CTCT: 34.50 (-0.38)
Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs
at Investor's Business Daily - Fri Oct 24, 9:52AM CDT
Stocks wobbled in and out of narrow gains early Friday. The Nasdaq, S&P 500 and Dow Jones industrials nibbled at 0.1% gains, but were tipping in and out of mixed trade. Nasdaq volume rose 38%. Trade on the NYSE was 13% below levels at the same time...
AMZN: 296.52 (-6.29), F: 13.94 (-0.01), SNCR: 50.53 (-0.27), GILD: 106.05 (-3.67), JAZZ: 167.18 (-1.30), ALTR: 35.35 (+0.54), BMY: 57.82 (-0.02), PG: 89.00 (+0.36), KLAC: 81.28 (+1.25), MSFT: 47.86 (+0.29), UPS: 107.54 (+0.46)
Facebook Among 10 IBD 50 Stocks With Rising Estimates
at Investor's Business Daily - Thu Oct 23, 9:43PM CDT
Facebook (FB) has been on a huge roll. But even with more than a billion users worldwide, the social networking giant wants more. CEO and founder Mark Zuckerberg stunned Chinese university students on Wednesday with a half-hour discussion in...
SNCR: 50.53 (-0.27), AKRX: 41.68 (-0.96), FB: 74.83 (-0.93), JAZZ: 167.18 (-1.30), ILMN: 186.37 (-5.04), NXPI: 73.36 (+3.69), TWTR: 40.37 (-0.53), AAPL: 108.86 (+0.26), BITA: 76.53 (-5.32), AVGO: 86.71 (+1.35), ADS: 284.02 (+5.91)
Jazz Pharmaceuticals to Report 2014 Third Quarter Financial Results on November 4, 2014
PR Newswire - Tue Oct 21, 3:05PM CDT
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 third quarter financial results on Tuesday, November 4, 2014, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to provide a business and financial update and discuss third quarter 2014 financial results.
JAZZ: 167.18 (-1.30)
Insider Trading Alert - AYI, MDSO And JAZZ Traded By Insiders
at The Street - Fri Oct 17, 9:15AM CDT
Stocks with insider trader activity include AYI, MDSO and JAZZ
AYI: 138.89 (+0.60), MDSO: 43.40 (-0.54), JAZZ: 167.18 (-1.30)
Concert Pharmaceuticals Announces Positive CTP-354 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:04PM CDT
Concert Pharmaceuticals, Inc. (CNCE) recently announced encouraging data from a phase I study on CTP-354.
AVNR: 13.00 (-0.41), SHPG: 198.61 (+2.99), JAZZ: 167.18 (-1.30), CNCE: 14.36 (-0.26)